| Prevention and treatment of postmenopausal osteoporosis SH Tella, JC Gallagher The Journal of steroid biochemistry and molecular biology 142, 155-170, 2014 | 920 | 2014 |
| Tumour-induced osteomalacia S Minisola, M Peacock, S Fukumoto, C Cipriani, J Pepe, SH Tella, ... Nature reviews Disease primers 3 (1), 1-15, 2017 | 246 | 2017 |
| Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data JE Blau, SH Tella, SI Taylor, KI Rother Diabetes/metabolism research and reviews 33 (8), e2924, 2017 | 222 | 2017 |
| Fibrous dysplasia for radiologists: beyond ground glass bone matrix YS Kushchayeva, SV Kushchayev, TY Glushko, SH Tella, OM Teytelboym, ... Insights into imaging 9, 1035-1056, 2018 | 145 | 2018 |
| Anti–PD-L1 treatment induced central diabetes insipidus C Zhao, SH Tella, J Del Rivero, A Kommalapati, I Ebenuwa, J Gulley, ... The Journal of Clinical Endocrinology & Metabolism 103 (2), 365-369, 2018 | 102 | 2018 |
| Second-line therapies in advanced biliary tract cancers SH Tella, A Kommalapati, MJ Borad, A Mahipal The Lancet Oncology 21 (1), e29-e41, 2020 | 92 | 2020 |
| FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice A Kommalapati, SH Tella, M Borad, M Javle, A Mahipal Cancers 13 (12), 2968, 2021 | 87 | 2021 |
| Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes A Kommalapati, SH Tella, M Durkin, RS Go, G Goyal Blood, The Journal of the American Society of Hematology 131 (2), 265-268, 2018 | 86 | 2018 |
| Contemporary management of localized resectable pancreatic cancer A Kommalapati, SH Tella, G Goyal, WW Ma, A Mahipal Cancers 10 (1), 24, 2018 | 79 | 2018 |
| Biological agents in management of osteoporosis SH Tella, JC Gallagher European journal of clinical pharmacology 70, 1291-1301, 2014 | 76 | 2014 |
| Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance SH Tella, MS Rendell Therapeutic advances in endocrinology and metabolism 6 (3), 109-134, 2015 | 71 | 2015 |
| DPP-4 inhibitors: focus on safety SH Tella, MS Rendell Expert opinion on drug safety 14 (1), 127-140, 2015 | 69 | 2015 |
| Medullary thyroid carcinoma: an update on imaging SV Kushchayev, YS Kushchayeva, SH Tella, T Glushko, K Pacak, ... Journal of thyroid research 2019, 2019 | 67 | 2019 |
| FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma A Mahipal, SH Tella, A Kommalapati, D Anaya, R Kim Cancer treatment reviews 78, 1-7, 2019 | 65 | 2019 |
| Predictors of survival in adrenocortical carcinoma: an analysis from the national cancer database SH Tella, A Kommalapati, S Yaturu, E Kebebew The Journal of Clinical Endocrinology & Metabolism 103 (9), 3566-3573, 2018 | 55 | 2018 |
| Profile of abaloparatide and its potential in the treatment of postmenopausal osteoporosis SH Tella, A Kommalapati, R Correa, SH Tella Cureus 9 (5), 2017 | 55 | 2017 |
| Novel targeted treatment options for advanced cholangiocarcinoma A Mahipal, A Kommalapati, SH Tella, A Lim, R Kim Expert opinion on investigational drugs 27 (9), 709-720, 2018 | 50 | 2018 |
| Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma S Chakrabarti, SH Tella, A Kommalapati, BM Huffman, S Yadav, IB Riaz, ... Journal of gastrointestinal oncology 10 (3), 554, 2019 | 47 | 2019 |
| Prevention and treatment of FGFR inhibitor-associated toxicities A Mahipal, SH Tella, A Kommalapati, J Yu, R Kim Critical Reviews in Oncology/Hematology 155, 103091, 2020 | 46 | 2020 |
| Reduced insulin clearance and insulin-degrading enzyme activity contribute to hyperinsulinemia in African Americans A Fosam, S Sikder, BS Abel, SH Tella, MF Walter, A Mari, R Muniyappa The Journal of Clinical Endocrinology & Metabolism 105 (4), e1835-e1846, 2020 | 44 | 2020 |
